TAK insider trading
NYSE HealthcareTAKEDA PHARMACEUTICAL CO LTD — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About TAKEDA PHARMACEUTICAL CO LTD
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Company website: www.takeda.com
TAK insider activity at a glance
FilingIQ has scored 79 insider transactions for TAK since Apr 27, 2026. The most recent filing in our index is dated Aug 19, 2026.
Across the full history, 0 open-market purchases
and 18 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TAK insider trades is 65.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TAK Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading TAK
13F funds holding TAK
Frequently asked
- How many insider trades does FilingIQ track for TAK?
- FilingIQ tracks 79 Form 4 insider transactions for TAK (TAKEDA PHARMACEUTICAL CO LTD), covering filings from Apr 27, 2026 onwards. 67 of those were filed in the last 90 days.
- Are TAK insiders net buyers or net sellers?
- Across the full Form 4 history for TAK, 0 transactions (0%) were open-market purchases and 18 (23%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TAK insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is TAK in?
- TAKEDA PHARMACEUTICAL CO LTD (TAK) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $51.68B.
Methodology & sources
Every TAK insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.